ARTICLE | Company News
Bio3 Research, Cephalon, Creabilis Therapeutics deal
December 12, 2005 8:00 AM UTC
CEPH received an exclusive option to develop and commercialize K252a, a preclinical kinase inhibitor to treat psoriasis and restenosis. The compound is being developed by Creabilis and Bio3. ...